Impact of past HBV exposure on virological response to combined interferon ribavirin therapy in patients with chronic HCV genotype 4

M. Said, M. S. El-Raziky, M. Abdel-Hamid, Y. Saad, M. Hashem, S. Zakaria, M. K. Mohamed, G. Esmat

.

DOI: 10.4236/ojim.2011.12010                

Abstract

Aim: is to investigate if past exposure to HBV in chronic HCV infection promotes the progression of liver disease and influences Interferon (INF) response or not. Methods: 185 patients with chronic HCV were recruited and randomized into 2 groups, group I was treated with PEG-IFN alfa-2b plus ribavirin and group II with 3 MU/TIW IFN alfa-2b plus ribavirin. All patients had HBsAg negative & patients had HBc Ab positive tested for HBsAb. Patients with HBc Ab (n = 37) were tested for serum HBV DNA. Pretreatment liver biopsy and Immunohistochemistry was performed for detection of HBsAg and HBcAg using monoclonal antibodies. Demographic and laboratory data were collected. Results: 70/185 (38%) patients had Anti-HBc, 37 (20%) had isolated anti-HBc and none of the 37 subjects with isolated anti-HBc had serum HBV DNA. Sustained Viral Response (SVR) was achieved in 32/70 (46%) and 46/115 (40%) in anti-HBc seropositive and seronegative patients respectively, in conventional IFN group SVR was 37% and 39% in past HBV exposed patients and unexposed respectively, in PEG IFN group SVR was 59% and 41% in past HBV exposed patients and unexposed respectively. Among anti-HBc and anti-HBs seropositive patients SVR was 10/12 [83%] and 4/21 [19%] p = 0.004 in PEG and conventional IFN respectively. Marked fibrosis was diagnosed in 20% past HBV exposed patients versus 10% in unexposed patients (p = 0.01). Conclusion: past HBV exposure promotes the progression of liver disease but has no effect on the SVR to antiviral therapy in chronic HCV genotype 4 patients.

Keywords

HCV Genotype 4; Past HBV Exposure; Response To Interferon Therapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ryan, K.J. and Ray, C.G. (Eds). (2004) Sherris medical microbiology. 4th Edition, McGraw Hill, 551-552.
[2]	Lauer, G.M. and Walker, B.D. (2001) Hepatitis C virus infection. New England Journal of Medicine, 345, 41-52. doi:10.1056/NEJM200107053450107
[3]	Seeff, L.B. (2002) Natural history of chronic hepatitis. Hepatology, 36, 35-46. doi:10.1053/jhep.2002.36806
[4]	Abdel-Aziz, F., Habib, M., Mohamed, M.K., Abdel- Hamid, M., Gamil, F., Madkour, S. et al. (2000) Hepatitis C virus (HCV) infection in a community in the Nile Delta: Population description and HCV prevalence. Hepatology, 32, 111-115. doi:10.1053/jhep.2000.8438
[5]	Habib, M., Mohamed, M.K., Abdel-Aziz, F., Magder, L.S., Abdel-Hamid, M., Gamil, F. et al. (2001) Hepatitis C virus infection in a community in the Nile Delta: Risk factors for seropositivity. Hepatology, 33, 248-253. doi:10.1053/jhep.2001.20797
[6]	Nafeh, M.A., Medhat, A., Shehata, M., Mikhail, N.N., Swifee, Y., Abdel-Hamid, M. et al. (2000) Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. American Journal of Tropical Medicine and Hygiene, 63, 236-241.
[7]	Medhat, A., Shehata, M., Magder, L.S., Mikhail, N., Abdel-Baki, L., Nafeh, M. et al. (2002) Hepatitis C in a community in Upper Egypt: Risk factors for infection. American Journal of Tropical Medicine and Hygiene, 66, 633-638.
[8]	Dusheiko, G.M. (1994) Progress in hepatitis C research. Lancet, 344, 605-606. doi:10.1016/S0140-6736(94)91984-4
[9]	McOmish, F., Yap, P.L., Dow, B.C., Follett, E.A., Seed, C., Keller, A.J. et al. (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. Journal of Clinical Microbiology, 32, 884-892.
[10]	Mellor, J., Holmes, E.C., Jarvis, L.M., Yap, P.L. and Simmonds, P. (1995) Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: Implications for virus classification. The International HCV Collaborative Study Group. Journal of General Virology, 76, 2493-2507.
[11]	Quinti, I., el-Salman, D., Monier, M.K., Hackbart, B.G., Darwish, M.S., el-Zamiaty, D. et al. (1997) HCV infection in Egyptian patients with acute hepatitis. Digestive Diseases and Sciences, 42, 2017-2023. doi:10.1023/A:1018897813268
[12]	Zekri, A.R., Bahnassy, A.A., Ramadan, A.S., El-Bassuoni, M., Badran, A., Madwar, M.A. (2001) Hepatitis C virus genotyping versus serotyping in Egyptian patients. Infection, 29, 24-26. doi:10.1007/s15010-001-0010-8
[13]	Farci, P., Alter, H.J., Wong, D.C., Miller, R.H., Govindarajan, S., Engle, R. et al. (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization. Proceedings of the National Academy of Sciences of the United States of America, 1, 7792-7796. doi:10.1073/pnas.91.16.7792
[14]	Weltman, M.D., Brotodihardjo, A., Crewe, E.B., Farrell, G.C., Bilous, M., Grierson, J.M. et al. (1995) Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. Journal of Viral Hepatitis, 2, 39-45. doi:10.1111/j.1365-2893.1995.tb00070.x
[15]	Liaw, Y.F. (1995) Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology, 22, 1101- 1108.
[16]	Fukuda, R., Ishimura, N., Niigaki, M., Hamamoto, S., Satoh, S., Tanaka, S. et al. (1999) Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: Clinical and virological significance. Journal of Medical Virology, 58, 201-207. doi:10.1002/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2
[17]	Mrani, S., Chemin, I., Menouar, K., Guillaud, O., Pradat, P., Borghi, G. et al. (2007) Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. Journal of Medical Virology, 79, 1075-1081. doi:10.1002/jmv.20943
[18]	Miura, Y., Shibuya, A., Adachi, S., Takeuchi, A., Tsuchihashi, T., Nakazawa, T. et al. (2008) Occult hepatitis B virus infection as a risk factor for hepatocellu- lar carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatology Research, 38, 546-556. doi:10.1111/j.1872-034X.2007.00316.x
[19]	Branco, F., Mattos, A.A., Coral, G.P., Vanderborght, B., Santos, D.E., Franca, P. et al. (2007) Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arquivos de Gastroenterologia, 44, 58-63. doi:10.1590/S0004-28032007000100013
[20]	Liang, T.J., Blum, H.E. and Wands, J.R. (1990) Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology, 12, 204-212.
[21]	Zhang, Y.Y., Hansson, B.G., Kuo, L.S., Widell, A. and Nordenfelt, E. (1993) Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology, 17, 538-544. doi:10.1002/hep.1840170403
[22]	Cacciola, I., Pollicino, T., Squadrito, G., Cerenzia, G., Orlando, M.E. and Raimondo, G. (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. New England Journal of Medicine, 341, 22-26. doi:10.1056/NEJM199907013410104
[23]	Zignego, A.L., Fontana, R., Puliti, S., Barbagli, S., Monti, M., Careccia, G. et al. (1997) Relevance of inapparent coinfection by hepatitis B virus in alpha interferon- treated patients with hepatitis C virus chronic hepatitis. Journal of Medical Virology, 51, 313-318.
[24]	Kamel, M.A., Miller, F.D., El Masry, A.G., Zakaria, S., Khattab, M., Essmat, G., et al. (1994) The epidemiology of Schistosoma mansoni, hepatitis B and hepatitis C infection in Egypt. Annals of Tropical Medicine and Parasitology, 88, 501-509.
[25]	El-Sayed, N.M., Gomatos, P.J., Rodier, G.R., Wierzba, T.F., Darwish, A., Khashaba, S. et al. (1996) Seropre- valence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus, human immuno- deficiency virus, and Treponema pallidum infections: Association of hepatitis C virus infections with specific regions of Egypt. American Journal of Tropical Medicine and Hygiene, 55, 179-184.
[26]	Gad, R.R., Males, S., El Makhzangy, H., Shouman, S., Hasan, A., Attala, A. et al. (2008) Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver International, 28, 1478-3223.
[27]	Abdel-Hamid, M., Edelman, D.C., Highsmith, W.E. et al. (1997) Optimization, assessment, and proposed use of a direct nested reverse transcribtion-polymease chain reaction protocol for the detection of hepatitis C virus. Journal of Human Virology, 1, 58-65.
[28]	Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R. et al. (2001) Peginter- feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958-965. doi:10.1016/S0140-6736(01)06102-5
[29]	Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gon?ales, F.L. Jr et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347, 975- 982. doi:10.1056/NEJMoa020047
[30]	Hadziyannis, S.J. and Koskinas, J.S. (2004) Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatology Research, 29, 129- 135. doi:10.1016/j.hepres.2004.02.011
[31]	Shobokshi, O.A. (2003) Hepatis C virus genotype 4. Saudi Medical Journal, 24, 79-80.
[32]	Alfaleh, F.Z., Hadad, Q., Khuroo, M.S., Algamedi, A., Alashgar, H. et al. (2004) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International, 24, 568-574. doi:10.1111/j.1478-3231.2004.0976.x
[33]	Kamal, S.M., El Tawil, A.A., Nakano, T., He, Q., Rasenack, J., Hakam, S.A. et al. (2005) Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut, 54, 858- 866. doi:10.1136/gut.2004.057182
[34]	Majda-Stanis?awska, E., Bednarek, M., Jó?wiak, B., Sidorkiewicz, M., Piekarska, A. and Kuydowicz, J.E. (2006) Effect of interferon alfa and ribavirin treatment on hepatitis C virus RNA in serum and peripheral blood mononuclear cells in children with chronic hepatitis C. Acta Gastroenterol Belg, 69, 187-190.